Clinical Microbiomics acquires MS-Omics
The research firm, particularly known for its work on clonal-level microbiome profiling, adds leading expertise in metabolite profiling from Denmark-based MS-Omics to further advance its systems biology platform and help researchers worldwide understand the microbiome and how to impact health and disease.
"There is an unmet need in the microbiome field for better solutions to integrate microbiome and metabolome data," says Anders Grøn, CEO at Clinical Microbiomics, "this demands a truly interdisciplinary approach – one that is made possible through this acquisition. We’re excited to engage with our network of researchers around the world to bring the new platform and services to work.”
The acquisition comes just days after the announcement that Seventure Partners, the global microbiome venture capital, has invested 10 million euros in the research company.
The investment, from Seventure's Health for Life Capital II fund, will be used to further advance the company's microbiome profiling and systems biology platform, and to expand the service offering within multi-omics data integration, as well as to build further presence across other key global markets starting with the US.
Advanced bioinformatics
Microbiome science is widely proposed as the next frontier in addressing our most urgent health challenges and organizations worldwide are exploring this potential by developing nutritional products, live-biotherapeutics, and diagnostic tests.
The microbiome impacts health via the metabolites that it produces or modifies. This includes secondary microbial metabolites, conversion of food and drugs, and human-derived metabolites such as bile acids. In fact, the microbiome is a major source of variation in the human metabolome.
This interplay is too complex to understand from the microbiome functional potential or the metabolome alone. Clinical Microbiomics is utilizing advanced bioinformatics and systems biology to integrate the two disciplines paving the way for new innovations.
Morten Danielsen, CEO at MS-Omics, commented: “This transaction is a big milestone for our companies. It is a result of a strategic dialogue where it became clear that together we would be uniquely positioned to address microbiome research questions across the field. Together, we will be in position to offer a differentiated portfolio of services, lead the way with innovative concepts designed specifically for the fast-growing microbiome field, and benefit from improved sales coverage around the world”
Importantly Clinical Microbiomics hosts the richest data-warehouse on the market with 30k+ samples linking 3M+ bacterial strains to clinical phenotypes.
The business is located in Medicon Valley, spanning eastern Denmark and southern Sweden, but its microbiome analysis services are offered worldwide to clients across sectors such as pharma, biotech, nutrition, food, feed, personal care, and consumer testing.
